Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients

Seunggu (Jude) Han, Isaac Yang, Brian J. Ahn, Jose J. Otero, Tarik Tihan, Michael W. McDermott, Mitchel S. Berger, Michael D. Prados, Andrew T. Parsa

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BACKGROUND: Primary gliosarcoma (PGS) is a rare central nervous system tumor with limited experience reported in the literature. In the current study, the authors present a modern series of confirmed PGS cases treated in the era of magnetic resonance imaging (MRI), after the accepted glioblastoma management of resection, radiation, and temozolomide. METHODS: Using a retrospective review, patients with confirmed PGS were identified (1996-2008). Cases were determined to be PGS by central pathology review using the 2007 World Health Organization criteria. Extensive chart review was performed to gather clinical and pathologic data on these cases. RESULTS: All but 1 patient had undergone a preoperative MRI, with 1 patient receiving a computed tomography scan due to a cardiac pacemaker. A total of 10 patients received radiotherapy with concurrent and adjuvant temozolomide chemotherapy, and 8 patients received radiotherapy alone or in combination with other chemotherapeutic agents. In 2 patients, the history of adjuvant treatment could not be confirmed. The overall median survival was 13.9 months (range, 2.2-22.9 months). Patients with gliosarcomas resembling meningioma were found to have a significantly prolonged median survival compared with patients harboring gliosarcoma resembling glioblastoma multiforme (16 months vs 9.6 months; P = .011). However, no difference in survival was noted between patients who received concurrent radiotherapy and temozolomide compared with those who did not (10.4 months vs 13.9 months; P = .946). CONCLUSIONS: The results of the current study support previous hypotheses that there are 2 distinct types of PGS. The type mimicking the appearance of a meningioma appears to carry a significantly more favorable prognosis, most likely due to an increased chance at achieving macroscopic total resection.

Original languageEnglish (US)
Pages (from-to)1358-1366
Number of pages9
JournalCancer
Volume116
Issue number5
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

Fingerprint

Gliosarcoma
temozolomide
Radiotherapy
Meningioma
Glioblastoma
Survival
Magnetic Resonance Imaging
Central Nervous System Neoplasms
Adjuvant Chemotherapy
History
Tomography
Radiation
Pathology

Keywords

  • Clinical outcome
  • Clinical subtype
  • Gliosarcoma
  • Primary gliosarcoma
  • Treatment modalities

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Han, S. J., Yang, I., Ahn, B. J., Otero, J. J., Tihan, T., McDermott, M. W., ... Parsa, A. T. (2010). Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer, 116(5), 1358-1366. https://doi.org/10.1002/cncr.24857

Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. / Han, Seunggu (Jude); Yang, Isaac; Ahn, Brian J.; Otero, Jose J.; Tihan, Tarik; McDermott, Michael W.; Berger, Mitchel S.; Prados, Michael D.; Parsa, Andrew T.

In: Cancer, Vol. 116, No. 5, 01.03.2010, p. 1358-1366.

Research output: Contribution to journalArticle

Han, SJ, Yang, I, Ahn, BJ, Otero, JJ, Tihan, T, McDermott, MW, Berger, MS, Prados, MD & Parsa, AT 2010, 'Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients', Cancer, vol. 116, no. 5, pp. 1358-1366. https://doi.org/10.1002/cncr.24857
Han SJ, Yang I, Ahn BJ, Otero JJ, Tihan T, McDermott MW et al. Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer. 2010 Mar 1;116(5):1358-1366. https://doi.org/10.1002/cncr.24857
Han, Seunggu (Jude) ; Yang, Isaac ; Ahn, Brian J. ; Otero, Jose J. ; Tihan, Tarik ; McDermott, Michael W. ; Berger, Mitchel S. ; Prados, Michael D. ; Parsa, Andrew T. / Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. In: Cancer. 2010 ; Vol. 116, No. 5. pp. 1358-1366.
@article{2c948baea9cc4153a77c219697c6fb82,
title = "Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients",
abstract = "BACKGROUND: Primary gliosarcoma (PGS) is a rare central nervous system tumor with limited experience reported in the literature. In the current study, the authors present a modern series of confirmed PGS cases treated in the era of magnetic resonance imaging (MRI), after the accepted glioblastoma management of resection, radiation, and temozolomide. METHODS: Using a retrospective review, patients with confirmed PGS were identified (1996-2008). Cases were determined to be PGS by central pathology review using the 2007 World Health Organization criteria. Extensive chart review was performed to gather clinical and pathologic data on these cases. RESULTS: All but 1 patient had undergone a preoperative MRI, with 1 patient receiving a computed tomography scan due to a cardiac pacemaker. A total of 10 patients received radiotherapy with concurrent and adjuvant temozolomide chemotherapy, and 8 patients received radiotherapy alone or in combination with other chemotherapeutic agents. In 2 patients, the history of adjuvant treatment could not be confirmed. The overall median survival was 13.9 months (range, 2.2-22.9 months). Patients with gliosarcomas resembling meningioma were found to have a significantly prolonged median survival compared with patients harboring gliosarcoma resembling glioblastoma multiforme (16 months vs 9.6 months; P = .011). However, no difference in survival was noted between patients who received concurrent radiotherapy and temozolomide compared with those who did not (10.4 months vs 13.9 months; P = .946). CONCLUSIONS: The results of the current study support previous hypotheses that there are 2 distinct types of PGS. The type mimicking the appearance of a meningioma appears to carry a significantly more favorable prognosis, most likely due to an increased chance at achieving macroscopic total resection.",
keywords = "Clinical outcome, Clinical subtype, Gliosarcoma, Primary gliosarcoma, Treatment modalities",
author = "Han, {Seunggu (Jude)} and Isaac Yang and Ahn, {Brian J.} and Otero, {Jose J.} and Tarik Tihan and McDermott, {Michael W.} and Berger, {Mitchel S.} and Prados, {Michael D.} and Parsa, {Andrew T.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1002/cncr.24857",
language = "English (US)",
volume = "116",
pages = "1358--1366",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients

AU - Han, Seunggu (Jude)

AU - Yang, Isaac

AU - Ahn, Brian J.

AU - Otero, Jose J.

AU - Tihan, Tarik

AU - McDermott, Michael W.

AU - Berger, Mitchel S.

AU - Prados, Michael D.

AU - Parsa, Andrew T.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - BACKGROUND: Primary gliosarcoma (PGS) is a rare central nervous system tumor with limited experience reported in the literature. In the current study, the authors present a modern series of confirmed PGS cases treated in the era of magnetic resonance imaging (MRI), after the accepted glioblastoma management of resection, radiation, and temozolomide. METHODS: Using a retrospective review, patients with confirmed PGS were identified (1996-2008). Cases were determined to be PGS by central pathology review using the 2007 World Health Organization criteria. Extensive chart review was performed to gather clinical and pathologic data on these cases. RESULTS: All but 1 patient had undergone a preoperative MRI, with 1 patient receiving a computed tomography scan due to a cardiac pacemaker. A total of 10 patients received radiotherapy with concurrent and adjuvant temozolomide chemotherapy, and 8 patients received radiotherapy alone or in combination with other chemotherapeutic agents. In 2 patients, the history of adjuvant treatment could not be confirmed. The overall median survival was 13.9 months (range, 2.2-22.9 months). Patients with gliosarcomas resembling meningioma were found to have a significantly prolonged median survival compared with patients harboring gliosarcoma resembling glioblastoma multiforme (16 months vs 9.6 months; P = .011). However, no difference in survival was noted between patients who received concurrent radiotherapy and temozolomide compared with those who did not (10.4 months vs 13.9 months; P = .946). CONCLUSIONS: The results of the current study support previous hypotheses that there are 2 distinct types of PGS. The type mimicking the appearance of a meningioma appears to carry a significantly more favorable prognosis, most likely due to an increased chance at achieving macroscopic total resection.

AB - BACKGROUND: Primary gliosarcoma (PGS) is a rare central nervous system tumor with limited experience reported in the literature. In the current study, the authors present a modern series of confirmed PGS cases treated in the era of magnetic resonance imaging (MRI), after the accepted glioblastoma management of resection, radiation, and temozolomide. METHODS: Using a retrospective review, patients with confirmed PGS were identified (1996-2008). Cases were determined to be PGS by central pathology review using the 2007 World Health Organization criteria. Extensive chart review was performed to gather clinical and pathologic data on these cases. RESULTS: All but 1 patient had undergone a preoperative MRI, with 1 patient receiving a computed tomography scan due to a cardiac pacemaker. A total of 10 patients received radiotherapy with concurrent and adjuvant temozolomide chemotherapy, and 8 patients received radiotherapy alone or in combination with other chemotherapeutic agents. In 2 patients, the history of adjuvant treatment could not be confirmed. The overall median survival was 13.9 months (range, 2.2-22.9 months). Patients with gliosarcomas resembling meningioma were found to have a significantly prolonged median survival compared with patients harboring gliosarcoma resembling glioblastoma multiforme (16 months vs 9.6 months; P = .011). However, no difference in survival was noted between patients who received concurrent radiotherapy and temozolomide compared with those who did not (10.4 months vs 13.9 months; P = .946). CONCLUSIONS: The results of the current study support previous hypotheses that there are 2 distinct types of PGS. The type mimicking the appearance of a meningioma appears to carry a significantly more favorable prognosis, most likely due to an increased chance at achieving macroscopic total resection.

KW - Clinical outcome

KW - Clinical subtype

KW - Gliosarcoma

KW - Primary gliosarcoma

KW - Treatment modalities

UR - http://www.scopus.com/inward/record.url?scp=77149163818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149163818&partnerID=8YFLogxK

U2 - 10.1002/cncr.24857

DO - 10.1002/cncr.24857

M3 - Article

VL - 116

SP - 1358

EP - 1366

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -